• news.cision.com/
  • SpectraCure/
  • Agreement reached between SpectraCure and one more hospital - Memorial Sloan Kettering Cancer Center i n New York

Agreement reached between SpectraCure and one more hospital - Memorial Sloan Kettering Cancer Center i n New York

Report this content

SpectraCure AB (publ) and Memorial Sloan Kettering Cancer Center in New York, USA, have today signed an agreement, which means that the hospital will be the fourth hospital in SpectraCure's clinical program. A formal meeting ("Site Initiation Visit") for the start-up and review of routines and equipment will be arranged between the company and the hospital next week. In connection with the signing of the agreement, SpectraCure makes a notification to the Food and Drug Administration (FDA) about adding a hospital and we estimate that Memorial Sloan Kettering Cancer Center may begin the study in early April.

The agreement with Memorial Sloan Kettering Cancer Center provides an opportunity to treat more patients at a faster rate, which increases the basis for analysis for further clinical studies and for future approval of the method by the authorities.

- Memorial Sloan Kettering Cancer Center is a very reputable and prestigious hospital with a high number of patients. We are very proud that they want to participate in our study. Discussions began during fall and our joint work has been intense to get everything in place so that they can begin treating patients, says SpectraCure's CEO Masoud Khayyami.

The goal of SpectraCure's clinical program is to evaluate SpectraCure’s treatment technology for recurrence of prostate cancer with so-called interstitial photodynamic therapy, PDT. The treatment involves giving the patient a drug that is activated locally in the prostate by SpectraCure's medical laser unit, creating destruction of the tumour tissue.

The study aims to show that the method is safe to use and gives a treatment effect on the cancer tumour. In the study, SpectraCure's unique technology – PDT treatment is used with the in-house developed dose planning platform IDOSE®, which solves the difficulty of controlling the laser light so that the cancer tumor is exposed to the right amount of light to achieve sufficient treatment effect.

For further information contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90. 

Certified Adviser is G&W Fondkommission, e-mailca@gwkapital.sephone: +46(0) 8 503 000 50.

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on March 6th, 2020 11:30.

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as “Interstitial Photodynamic Therapy”, PDT, a treatment methodology suitable for internal solid tumors of various kind e.g. prostate and abdominal glands, but also other indications such as cancer tumors in the head and neck region. www.spectracure.se